Tags

Type your tag names separated by a space and hit enter

Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists.
QJM. 2005 Mar; 98(3):171-82.QJM

Abstract

Although asthma is one of the most common chronic respiratory conditions, it often remains unrecognized and undertreated, while patients are often reluctant to comply with regular inhaled anti-inflammatory and bronchodilator therapy. Allergic rhinitis co-exists with asthma in as many as 40% of patients, and can be regarded as a continuum of the same inflammatory disease process. Corticosteroids are the 'gold standard' first-line treatment for both conditions, and have a significant impact upon underlying inflammation, symptoms and long-term outcome. Cysteinyl leukotrienes are potent airway inflammatory mediators, suggesting that treatment antagonizing their effects could play a role in disease management. In recent years, leukotriene receptor antagonists have provided a further therapeutic option in the management of allergic airways disease. These drugs are orally active, can be administered once daily, and provide a systemic approach to the management of patients with asthma and allergic rhinitis. We review the pharmacology of leukotriene receptor antagonists, their potential role in clinical practice in patients with allergic airways disease, and likely areas for further research.

Authors+Show Affiliations

Department of Respiratory Medicine, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN. graeme_currie@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15728398

Citation

Currie, G P., et al. "Therapeutic Modulation of Allergic Airways Disease With Leukotriene Receptor Antagonists." QJM : Monthly Journal of the Association of Physicians, vol. 98, no. 3, 2005, pp. 171-82.
Currie GP, Srivastava P, Dempsey OJ, et al. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. QJM. 2005;98(3):171-82.
Currie, G. P., Srivastava, P., Dempsey, O. J., & Lee, D. K. (2005). Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. QJM : Monthly Journal of the Association of Physicians, 98(3), 171-82.
Currie GP, et al. Therapeutic Modulation of Allergic Airways Disease With Leukotriene Receptor Antagonists. QJM. 2005;98(3):171-82. PubMed PMID: 15728398.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. AU - Currie,G P, AU - Srivastava,P, AU - Dempsey,O J, AU - Lee,D K C, PY - 2005/2/25/pubmed PY - 2005/6/17/medline PY - 2005/2/25/entrez SP - 171 EP - 82 JF - QJM : monthly journal of the Association of Physicians JO - QJM VL - 98 IS - 3 N2 - Although asthma is one of the most common chronic respiratory conditions, it often remains unrecognized and undertreated, while patients are often reluctant to comply with regular inhaled anti-inflammatory and bronchodilator therapy. Allergic rhinitis co-exists with asthma in as many as 40% of patients, and can be regarded as a continuum of the same inflammatory disease process. Corticosteroids are the 'gold standard' first-line treatment for both conditions, and have a significant impact upon underlying inflammation, symptoms and long-term outcome. Cysteinyl leukotrienes are potent airway inflammatory mediators, suggesting that treatment antagonizing their effects could play a role in disease management. In recent years, leukotriene receptor antagonists have provided a further therapeutic option in the management of allergic airways disease. These drugs are orally active, can be administered once daily, and provide a systemic approach to the management of patients with asthma and allergic rhinitis. We review the pharmacology of leukotriene receptor antagonists, their potential role in clinical practice in patients with allergic airways disease, and likely areas for further research. SN - 1460-2725 UR - https://www.unboundmedicine.com/medline/citation/15728398/Therapeutic_modulation_of_allergic_airways_disease_with_leukotriene_receptor_antagonists_ L2 - https://academic.oup.com/qjmed/article-lookup/doi/10.1093/qjmed/hci024 DB - PRIME DP - Unbound Medicine ER -